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RESUMEN
El acido esteárico: un posible sustituto para los áci-
dos grasos trans de origen industrial.
Los isómeros trans que contienen los aceites parcial-
mente hidrogenados de origen industrial, han sido cuestiona-
dos y la recomendación es reducir su consumo. La industria 
de alimentos se enfrenta a un dilema, ya que para disminuir 
los isómeros trans debe reducir los aceites parcialmente hi-
drogenados y reemplazarlos por grasas ricas en ácidos gra-
sos saturados. La investigación ha demostrado que los áci-
dos grasos saturados tienen efecto negativo en los lípidos 
plasmáticos y su consumo se asocia con un alto riesgo car-
diovascular, por lo cual la recomendación es reducir el con-
sumo de estos ácidos grasos. Sin embargo, no todos los áci-
dos grasos saturados se comportan de la misma forma, 
siendo el ácido esteárico (18:0) la excepción. El ácido esteá-
rico presenta bajo nivel de absorción intestinal y no modifica 
negativamente los lípidos plasmáticos, por lo cual se consi-
dera como “neutro” para la salud cardiovascular. Los niveles 
plasmáticos de la apoproteína B-100, que determina las con-
centraciones de las VLDL y LDL (transportadoras de triglicé-
ridos y colesterol, respectivamente) no son modificados por 
dietas que aportan hasta 7% de la energía como ácido es-
teárico. Marcadores de riesgo cardiovascular, como la acti-
vación de factores de agregación plaquetaria o los niveles de 
la proteína C reactiva, no son modificados por dietas que 
aportan ácido esteárico, como ocurre con otros ácidos gra-
sos saturados. La confirmación del efecto “neutro” del ácido 
esteárico es una perspectiva para el desarrollo de grasas 
con alto contenido de este ácido graso para reemplazar las 
grasas hidrogenadas que contienen isómeros trans. Esta re-
visión discute estos aspectos.
PALABRAS-CLAVE: Ácido esteárico – Alternativa a las 
grasas hidrogenadas – Efecto metabólico neutro – Isómeros 
trans – Salud cardiovascular.
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and nowadays trends are heading towards reducing their 
consumption. The food industry is facing a dilemma, since in 
order to remove trans fatty acids, hydrogenated fats should 
be eliminated and replaced by fats rich in saturated fatty 
acids. Scientific research has shown that saturated fatty acids 
have negative effects on the lipid profile and its consumption 
is associated with a higher cardiovascular risk. Therefore it 
is recommended to avoid their consumption. Nevertheless, 
not all fatty acids behave in the same way, with stearic acid 
(18:0) the exception. Stearic acid has a low level of intestinal 
absorption and its intake does not negatively modify the lipid 
profile. For this reason, it is considered a “neutral” fatty acid 
with regard to cardiovascular health. B-100 apolipoprotein, 
whose levels determine plasma VLDL and LDL concentration 
(triglycerides and cholesterol carriers, respectively), is not 
modified by diets which provide up to 7% of the energy 
as stearic acid. Markers of cardiovascular risk, such as 
activation of platelet aggregation factors or C-reactive protein 
levels, are not modified by diets providing stearic acid, as 
occurs with other saturated fatty acids. The confirmation of 
the “neutral” effect of stearic acid represents a perspective for 
the development of fats with high contents of this fatty acid 
to replace hydrogenated fats containing trans isomers. The 
present review discusses these aspects. 
KEY-WORDS: Alternatives to hydrogenated fats – 
Cardiovascular health – “Neutral” metabolic effect – Stearic 
acid – trans Isomers.
1. INTRODUCTION
The dietary consumption of fatty acids with trans 
isomerism (TFA) has been called into question by 
health and food authorities due to their adverse 
effects on overall health and mainly on cardiovascular 
health derived from their consumption (Ascherio et 
al., 1996; Hu et al., 1997; Hunter, 2006; Mozaffarian 
et al., 2009). Several epidemiological and clinical 
studies have unmistakably demonstrated that 
TFA acids produce an increase in plasmatic total 
cholesterol levels, in LDL-cholesterol levels (bad 
cholesterol) and in total triglycerides (Kris-Etherton 
et al., 2005; Mozaffarian et al., 2006; Hunter, 2006). 
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Etherton et al., 2005), thus explaining in part 
the difference derived from estimates based on 
controlled dietary interventions focusing mainly 
on serum cholesterol fractions versus prospective 
cohort studies having cardiovascular disease 
events as their main outcome (Hunter et al., 2010). 
It is important to highlight that in Europe, the 
starting point was in the early 1990s, when the TFA 
reduction in certain margarines was implemented 
by means of suppressing partially hydrogenated 
fats (Morin, 2007). This situation has been envied 
by Americans and in 1994 Harvard researchers, 
lead by epidemiologist Walter Willett, encouraged 
people to join the European initiative (Ascherio et 
al., 1996). Willett´s group urged Americans to stop 
eating TFA and encouraged the Food and Drug 
Administration (FDA) to add them to food labels, a 
step the agency considered (Ascherio et al., 1996). 
The same researchers also urged companies to 
follow Europe’s lead in improving hydrogenation 
and producing margarine without TFA (Hu et al., 
1997). Most recent food surveys pointed out that 
TFA consumption had effectively decreased in 
several European countries mainly due to the 
reformulation of several food products, for example 
spreads (Korver & Katan, 2006). 
2.  TFA ISOMERS ORIGIN  
AND CONSUMPTION
TFA isomers have two main origins: biological 
and technological (Valenzuela & Morgado, 1999). 
Biological ones come from products derived from 
ruminant animals (beef, beef tallow, milk and its 
derived products), and they do not involve more 
than 5-10% of the total consumption of TFA isomers 
in European and American countries (Larqué et al., 
2001). Therefore, in these countries TFA intake 
comes essentially from technological sources, (90-
95%) mainly hydrogenated fats, frying processes 
and to a lesser degree from edible oils which are 
treated with a deodorization process (Larqué et al., 
2001; Craig-Schmidt, 2006). Current guidelines 
recommend an intake lower than 1% of the energy 
as TFA (Eckel et al., 2007). In the United States 
current consumption is around 2.5-3% of the total 
energy, meaning 5.8-6.0g/day (Allison et al., 1999), 
although it might reach 10g/day or more in some 
segments of the population. Consumption in Latin 
America varies remarkably from country to country, 
but the average is around 4.5-5.0 g/day (Valenzuela, 
2008a). Consumption in European countries varies 
depending on the country as well, but it is generally 
lower than in American countries, ranging from 
1.4 to 5.0g/day in a remarkable decreasing rate 
from North to South (higher in the North than in 
the South, eg: Netherlands vs Spain) (Kromhout 
et al., 1995; Hutshof et al., 1999). The TFA source 
is completely different in Europe. A great deal of 
TFA fat has animal origin (40 to 60% vs. 5 to 10% 
in the US), also with a significant decreasing rate 
from North to South. Animal products are the main 
It has been also demonstrated that TFA reduce 
HDL-cholesterol levels (good cholesterol) (Hu et 
al., 1997). There is also evidence that TFA can 
increase type 2 diabetes complications (Salmeron 
et al., 2001; Tanasescu et al., 2004; Saravanan 
et al., 2005). These effects have a negative 
incidence on health, for they increase in the risk of 
cardiovascular diseases, which are the main reason 
for death in the population of the western world. 
Nowadays, it is considered that the TFA negative 
effect on health can be at least compared with the 
effect of saturated fatty acids (SAFA) (Sundran et 
al., 1997; Hu et al., 1997; Valenzuela & Morgado., 
1999; Judd et al., 2002; Hunter, 2006). According 
to epidemiological studies and in order to avoid a 
possible incidence of cardiovascular risk, health 
authorities have proposed to limit TFA consumption 
to 2% of the total energy supply (US FDA, 2003; 
Uauy et al., 2009).
Different countries have adopted policies 
aiming at a drastic reduction in TFA consumption 
in their populations (Stender et al., 2006). Since 
June 1st 2003, Denmark has forbidden any content 
higher than 2% of TFA in both locally produced 
and imported fats hence the use of partially 
hydrogenated fats has been essentially eliminated 
from this country (Leth et al., 2005). Countries 
such as Norway, Finland, and the Netherlands 
have similar initiatives (Aro, 2005). Since 2003, 
Canada has become the first country in America 
to regulate the compulsory labelling of TFA and 
in 2006 it was proposed that TFA should not 
exceed 2% of the total fat content in vegetable 
oils and soft margarines for spread, and 5% of 
the total fat content in other foods. The United 
States introduced the compulsory labelling of TFA 
in 2006 (Eckel et al., 2007), an initiative that was 
followed by many other countries in Latin America, 
mainly MERCOSUR countries (Argentine, Brazil, 
Paraguay and Uruguay), and Chile (Valenzuela, 
2008). Important fast food chains have withdrawn 
TFA from their products in different Latin American 
countries (Argentina, Brazil, Chile, Uruguay) 
(Valenzuela, 2008a). Most recently, the state of 
New York, in the United States, banned the use of 
hydrogenated products containing TFA in fast food 
restaurants. In response to these requirements, 
different industrial and fast food companies have 
announced the removal or future elimination of fats 
containing TFA in their products (Korver & Katan, 
2006; Mozaffarian & Clarke, 2009). 
In recent years, The World Health Organization 
(WHO) has held three meetings of Scientific Update 
on the elimination of TFA: PAHO (Pan American 
Health Organization) meeting, Washington DC, 
USA, August 2007; PAHO meeting, Washington, 
DC, USA, November 2007; and WHO meeting, 
in Geneva, Italy, February 2008. Their findings 
indicate that the replacement of TFA in partially 
hydrogenated vegetable oil with alternative fats 
and oils would substantially lower cardiovascular 
disease risk through multiple mechanisms beyond 
those on cholesterol-lipoprotein fractions (Kris-
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3. STA, A “DIFFERENT” FATTY ACID
STA is a saturated fatty acid present in fats of 
both animal and vegetal origin. Following palmitic 
acid (C16:0), it is the most widely consumed fatty 
acid in the United States as well as in the Western 
population in general (Ervin et al., 2004). Palmitic 
acid (16:0) amounts to 56% of the total consumption 
and stearic acid 26%, approximately. The rest of 
the SFA consumption consists of myristic (C14:0), 
and lauric acid (C12:0), and in lower quantities 
butyric (C4:0), capric (C10:0), caproic (C6:0), and 
caprylic acid (C8:0). STA is taken from animal fat 
(bovine, porcine, ovine and marine fish), and in 
lower amounts from vegetable fats (coconut oil, 
soybean oil, corn oil, cocoa butter, etc). Figure 1 
shows the STA contents in different fats of regular 
consumption.
Fatty acid absorption into the human digestive 
system essentially depends on the position that 
fatty acids have in dietary triglycerides (Mu & 
Hø´y, 2004), which amount to 90-95% of our fat 
consumption. The rest of our intake consists 
of phospholipids (3.5-4%), and different sterols 
(1.5-2%), such as cholesterol, phytosterols, 
phytostanols, etc. (Carroll, 1958). In animal fats, 
SAFAs usually occupy sn-1 and sn-3 positions 
of triglycerides, and in a lower proportion they 
are found in the sn-2 position (Bracco, 1994). In 
bovine, porcine and ovine fats, STA is much more 
frequently found in the sn-1 and sn-3, than in the 
sn-2 position. In vegetable fats, SAFAs, especially 
STAs, mainly occupy the sn-1 and sn-3 positions of 
triglycerides as well (Mattson & Volpenhein, 1964). 
The sn-2 Position of these fats and oils is frequently 
occupied by unsaturated fatty acids, such as oleic 
acid (C18:1) and less frequently by linoleic (C18:2), 
source with 60%; dairy products around 50% (butter 
35% and cheese 17%) and ruminants beef 10%. 
Biscuits, pastry, industrial bakery and cooked dishes 
come next with 30-40% (Husthof et al., 1999). An 
important issue to highlight is that the information 
gathered from countries that recently joined the 
European Union shows that Eastern European 
countries seem to have a much higher consumption 
than in Western Europe.
From the food industry point of view, it is very 
difficult to reduce the use of hydrogenated fats, 
the main source of TFA isomers, since these fats 
are essential for the manufacturing of several food 
products. Hydrogenated fats work as a base for 
adding other nutrients, they have thermal stability, 
they provide palatability and crispy characteristics 
to products, etc (Valenzuela & Morgado, 1999; 
Korver & Katan, 2006). In this way, it is currently 
a challenge for the food industry to substitute 
TFA present in their products without altering 
organoleptic characteristics such as appearance 
and stability. Within the few available alternatives to 
this possible replacement, the ones most commonly 
found are mainly oils with low polyunsaturated fatty 
acid contents, or with high SAFA contents (palm 
oil, high oleic sunflower oil, low linoleic soybean 
oil, etc.) (Tarragó-Trani et al., 2006). However, 
nowadays, stearic acid (C18:0) (STA) turns out 
to be a recent alternative with great significance 
(Hunter et al., 2010). How could an SAFA replace 
TFA isomers? The purpose of this review is to 
analyze the evidence of the neutral effects of STA 
in lipid and vascular parameters which constitute 
the markers of cardiovascular disease risk, and to 
state the reason why this fatty acid contained in 
fats can constitute a reasonable alternative for the 
substitution of TFA in our diet. 
Figure 1
 Common fatty acids in edible fats and oils. MUFA: monounsaturated fatty acids.
Modified from Kris-Etherton et al., 2005.
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low digestibility fat and its consumption produces 
the elimination of high quantities of STA through 
depositions (Finley et al., 1994). This characteristic 
has made it a popular low calorie fat. However, 
when SALATRIM is previously randomized through 
interesterification, the molecule loses symmetry 
and thus leaves a significant proportion of STA in 
the s-2 position. When the resulting products effect 
is tested, the fatty acid also shows low absorption 
(Berry & Sanders, 2005). Hence, it is suggested 
that regardless of the position STA occupies in 
triglycerides (sn-1, sn-2 or sn-3), its intestinal 
absorption is always low (Berry & Sanders, 2005; 
Berry et al., 2007). 
It has been proposed that STA would be a 
bad substrate for acyl-cholesterol-acyl-transferase 
enzyme (ACAT) which is responsible for cholesterol 
re-esterification in the intestine (Daumerie et al., 
1992). If cholesterol is not re-esterified into intestine 
cells, it is again transported to the intestinal lumen 
and eliminated with faeces (Rodríguez-Meléndez et 
al., 2006). It has also been proposed that STA would 
enhance cholesterol hepatic excretion through bile 
(Imaizumi et al., 1993), although this increase does 
not occur experimentally in hamsters (Hassel et al., 
1997). Moreover, it has been demonstrated that 
STA inhibits the expression of the Nieman-Pick C1 
L1 transporter (NPC1L1) in the FH 74 cell line of 
intestinal cells (Hunter 2001). This transporter is 
responsible for carrying cholesterol from intestinal 
lumen to the enterocyte (Rodríguez-Meléndez et 
al., 2006). As a result of both mechanisms, lower 
cholesterol absorption at the intestinal level would 
be produced due to the effect of STA. 
4.1. Effects on plasmatic lipids
Predictive equations for the differential effects 
of fatty acids on plasmatic lipids developed 
independently by Keys et al., (1965) and Hegsted 
et al., (1965) several decades ago, demonstrated 
the hypercholesterolemic effect of SAFA and 
its consequent increase in cardiovascular risk. 
However, when these equations were applied to 
STA, the fatty acid appeared with a “neutral” effect 
on plasmatic cholesterol levels. More complex 
mathematical equations, like the one developed by 
Mensink y Katan (1992), demonstrated the neutral 
effect of the fatty acid, not only on total cholesterol, 
but also on LDL- and HDL- cholesterol levels. 
Similar results were obtained by Yu et al. (1995), 
who developed new predictive formulae starting 
from regression studies, concluding that STA has 
a neutral effect on the lipid profile in men as well 
as in women. Moreover, when comparing its effect 
with lauric, palmitic or myristic acid, STA shows a 
neutral or slightly positive effect on plasmatic lipids 
(Hunter, 2001). A meta-analysis carried out by 
Mensink et al. (2003) on 60 controlled clinical trials 
compared the effect of SAFA on the modification 
of plasmatic lipids with respect to their substitution 
by carbohydrates in the diet. It was demonstrated 
that STA reduces cholesterol plasmatic levels and 
and alpha linolenic (C18:3) acids (Christie & 
Moore, 1972). This special stereoisomerism has an 
important impact on the absorption degree of each 
fatty acid in the human small intestine (Kubow, 
1996; Hunter, 2001).
Human digestive lipases, both lingual, gastric, 
as well as pancreatic, have special specificity to 
hydrolyze the sn-1 and sn-3 positions of dietary 
triglycerides (Bracco, 1994; Hunter, 2001), in such 
a way that less than 20% of the triglycerides are 
totally hydrolyzed into free fatty acids and glycerol 
(Mu & Hø´y, 2004). In this way, the main products of 
triglyceride intestinal hydrolysis are monoglycerides 
with sn-2 sterified fatty acids, and fatty acids 
released from the sn-1 and sn-3 positions. This is 
how STA, released from both animal and vegetal 
fats, will be present in the small intestine lumen, 
after the digestive process, primarily in a free form 
and secondarily as part of sn-2 monoglycerides 
(Kritchevsky, 1994; Hunter, 2001). When STA is 
located in the sn-2 position in the triglycerides it is 
well absorbed, but when found in the sn-1 or sn-3 
positions it is only partially absorbed, ranging from 
37 to 55% (Mattson et al., 1979).
4. STA DIGESTION AND ABSORPTION 
Studies have demonstrated that, comparatively, 
STA is absorbed in a lower proportion than other 
SAFAs such as lauric, myristic and palmitic, and 
even MUFA, as oleic, or type C18:1 TFA isomers 
(Baer, 2003). The general conclusion is that STA is 
less absorbed than other dietary SAFAs, therefore 
its plasmatic concentration would be lower when 
compared with the ones obtained with similar 
amounts of other SAFAs (Kris-Etherton et al., 
1997; Kris-Etherton et al., 2005). The reason for 
the reduction in the presence of STA at plasmatic 
level, compared with equivalent amounts of 
other SAFAs, is not yet fully known (German & 
Dillard, 2004). It has been postulated that due 
to its relatively high melting point (70°C), when 
released into the intestinal lumen under the effect 
of enzymatic hydrolysis, it would form calcium 
and/or magnesium insoluble salts, which would 
be eliminated through depositions (Mattson et al., 
1979). Other researchers have also postulated 
that a certain percentage of absorbed STA would 
be turned into oleic acid through intestinal cell 
desaturation (Garg, 1992). This transformation has 
been estimated to be around 9% and 14% (Rhee 
et al., 1997). Whatever the reason might be, the 
point is that STA absorption is lower than that of 
SAFA with fewer carbon atoms (Kris-Etherton 
et al., 2005), particularly when found in sn-1 and 
sn-3 positions. Nevertheless, the lower absorption 
is not exclusive when STA takes up these 
triglyceride positions. SALATRIM is a structured 
lipid which contains long chain SAFAs, mainly STA, 
in sn-1 and sn-3 positions, and short chain fatty 
acids (acetic, propionic and/or butyric) in the sn-2 
position. For this reason, SALATRIM is a proved 
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relationship between TFA and lipoprotein (a) are 
needed. 
4.2.  STA, activation of thrombogenic factors 
and blood pressure
The activation of thrombogenic factors due to 
post-prandial lipemia effect has been associated 
with an increase in cardiovascular risk. A meal rich 
in STA increases lipemia, but to lower levels than 
lipemia resulting from taking oleic and elaidic acids 
(Sanders et al., 2000), or palmitic acid (Mennen et 
al., 1998), probably due to the low absorption effect 
of STA already discussed. The increase in post-
prandial lipemia raised the concentration of Factor 
VIIc activated form, a coagulation factor dependent 
on vitamin K. Fatty acids in general increase the 
activation of this Factor (Mitropoulos et al., 1994; 
Mennen et al., 1998). However, comparatively, 
STA produces a lower activation of this factor than 
oleic acid, as observed by Tholstrup et al. (1994) 
and later confirmed by Sanders et al. (2000); also 
lower than palmitic acid (Mennen et al., 1998). 
The effect of STA on hemodynamics is still not 
clear and in some cases is controversial. Multiple 
intervention studies have demonstrated an inverse 
correlation between cholesterol plasmatic levels 
and STA, and the diastolic pressure measured in 
middle-aged individuals with high cardiovascular 
disease risk (Simon et al., 1996). However, when 
this measurement is made on healthy individuals, 
both plasmatic cholesterol as well as STA levels 
significantly increases left ventricular diastolic 
pressure (Steer et al., 2002). Controlled clinical 
trials demonstrate that diets with 8 to 13% of the 
total energy as STA, have no effect on vascular 
pressure measured in diabetic patients (Storm 
et al., 1997), or in men and women with vascular 
pressure at normal ranges (zock et al., 1993). This 
information is important because it corresponds to 
studies with standard STA intakes. 
Finally, there is little evidence on the effect of 
STA on molecular markers of inflammation, such 
as cytokines (interleukine-6, for example), adhesion 
molecules (such as selectins), or acute-phase 
expression proteins (such as C-reactive protein), 
which are important to predict cardiovascular 
disease (Blake & Ridker, 2002). STA does not 
modify plasmatic levels of these molecular markers 
if the diet imparts 11% of its energy as STA (Baer 
et al., 2004), although it does increase fibrinogen 
levels when taking in 11% of the energy as STA 
(Baer et al, 2004). Nevertheless, Kris-Eherton et al 
(2005) do not consider this last point relevant due to 
the fact that the average consumption STA is lower 
than 3% of the energy (Ervin et al., 2004). Thijssen 
et al. (2005) demonstrated that diets with 7% of 
the energy as STA, which is significantly higher 
than average consumption (3%), do not affect 
blood platelet aggregation. Therefore, researchers 
conclude that STA would not have thrombogenic 
effects, making it comparable to oleic or linoleic 
acid. 
the relationship between total cholesterol and HDL-
cholesterol. The modification of both parameters is 
a positive marker for reduced cardiovascular risk. 
Similar studies have demonstrated that dietary 
STA, contributing from 9% to 40% of the total 
energy, does not modify total plasmatic cholesterol, 
and even in some cases it is reduced (Aro et al., 
1997; Nestel et al., 1998; Snook et al., 1999). A 
more recent study by Thijssen & Mensink (2005), 
showed that diets with 7% of STA produce changes 
in the lipid profile similar to those yielded by a diet 
having an equal amount of oleic or linoleic acid. In 
this work, a detailed evaluation on the lipoprotein 
profile was carried out by Nuclear Magnetic 
Resonance (NMR), showing that the three fatty 
acids have similar effects on total and LDL-
cholesterol reduction. Surprisingly for researchers, 
STA also increased HDL-cholesterol, an effect 
which has been previously observed only with oleic 
and linoleic acids. Another remarkable observation 
on Thijssen & Mensink’s work (2005) is that STA 
does not modify LDL size, that is, it does not 
increase smaller sized LDLs, which are considered 
more atherogenic than larger sized LDLs (Gardner 
et al., 1996). The experimental protocol used by 
Thijssen & Mensink involved fats only from natural 
origin, where STA mainly occupies sn-1 and sn-
3 positions. A more recent work by Sundran et al 
(2007), demonstrates that an interesterified fat, with 
a high proportion of STA (40%), negatively modifies 
the lipid profile, also increasing the plasmatic 
glucose levels. However, an analysis on the fatty 
acid triglyceride sterochemistry, shows that 15% of 
STA is in the sn-2 position. This result emphasizes 
the concept that the beneficial effects derived from 
STA are obtained when it takes up sn-1 and sn-3 
of triglyceride positions. An equal effect to other 
saturated fatty acids is observed when it is located 
in the sn-2 position (Sundran et al., 2007). 
Apolipoproteins make up the protein part of 
lipoproteins and enable the selective recognition 
of these proteins by different tissues. B-100 
apolipoprotein (ApoB-100) is only present in VLDL 
and LDL which derive from VLDL. In this way, 
high levels of ApoB-100 are indicative of an active 
triglyceride (by VLDL) and cholesterol (by LDL) 
transport. On the contrary, low ApoB-100 plasmatic 
levels mean low VLDL and LDL concentrations. 
Two studies demonstrated that when STA provides 
either 9.3% or 36% of the energy, a reduction in 
ApoB-100 from 10% to 18% is produced (Tholstrup 
et al., 1994; Aro et al., 1997). However, the latter 
study also demonstrated that STA increases 
lipoprotein (a) plasmatic levels. This type of 
lipoprotein has similar characteristics to LDL, which 
is related to a higher atherogenicity and considered 
an emerging marker of cardiovascular disease 
(Clevidence et al., 1997). This effect has also 
been shown by a study on fasting (Tholstrup et al., 
1995), and in post-prandial conditions (Tholstrup & 
Samman, 2004). The available data concerning the 
changes in lipoprotein (a) concentration with dietary 
TFA are limited, and further studies concerning a 
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5. FINAL CONSIDERATIONS 
There is a clear need to alert oil seed producers 
that there will likely be a requirement for an increased 
supply of substitute oils in order to replace TFA 
and that this represents an opportunity to expand 
or develop new oil seed varieties. The results of 
scientific updates should provide the evidence and 
scientific bases to promote discussions between the 
international scientific community related to nutrition 
and health as well as to agriculturalists and the food 
production industry, relevant health professionals, 
national and international food regulatory agencies, 
civil society, and the private sector in order to 
achieve this goal.
Available information, derived from experimental, 
clinical and epidemiological research, enables us to 
confirm with reasonable evidence, that when STA 
is consumed in less than 7% of the total energy, 
lipid profile, thrombotic factors, hemodynamic and 
cardiovascular risk molecular markers are not 
modified (Kris-Etherton et al., 2005; Hunter et al., 
2010). This aspect distinguishes STA from other 
SAFAs present in diets, such as palmitic, lauric and 
myristic, while it ranks among MUFAs, such as oleic 
acid, or polyunsaturated acids, such as linoleic acid. 
The reason for this “neutral” effect is still unclear, 
and could be assigned to different factors: a lower 
absorption and higher excretion in the intestinal 
lumen when located in the sn-1 and sn-3 positions 
of dietary triglycerides; a partial conversion into 
oleic acid through intestine cell desaturation; to 
an inhibitory effect on ApoB-100 synthesis; or to 
other factors not yet identified. Everything focuses 
on the fact that fats with a high proportion of STA 
in the sn-1 and sn-3 positions could be very good 
substitutes for hydrogenated fats with high contents 
of TFA isomers. It should be pointed out that the 
neutral effect on cardiovascular diseases attributed 
to chocolate consumption would be due, in some 
degree, to a high proportion of STA in the sn-1 and 
sn-3 positions found in cocoa butter, together with 
its high cytoprotective flavonoids content (Ding 
et al., 2006). Oils with high STA content in the sn-
1 and sn-3 triglyceride position for frying use, are 
high temperature resistant due to their saturated 
characteristics. These could be an adequate 
substitute for partially hydrogenated fats with high 
contents of TFA isomers, which are nowadays used 
in the food industry and mainly for frying processes in 
fast food chains (DiRienzo et al., 2008). In summary, 
we conclude that STA may be a reasonable 
substitute for TFA and also for cholesterol-raising 
SAFAs for solid fat applications, such as baked 
goods, shortenings, spreads, and margarines.
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